GENE-EXPRESSION AND RELEASE OF INTERLEUKIN-8 BY PERITONEAL-MACROPHAGES AND POLYMORPHONUCLEAR LEUKOCYTES DURING PERITONITIS IN UREMIC PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

被引:12
|
作者
LIN, CY
HUANG, TP
机构
[1] NATL YANG MING MED COLL,DEPT MED RES,TAIPEI 11221,TAIWAN
[2] NATL YANG MING MED COLL,DEPT PEDIAT,TAIPEI 11221,TAIWAN
[3] VET GEN HOSP,DEPT MED,NEPHROL SECT,TAIPEI,TAIWAN
来源
NEPHRON | 1994年 / 68卷 / 04期
关键词
PERITONEAL MACROPHAGE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; INTERLEUKIN-8;
D O I
10.1159/000188304
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Interleukin-8 (IL-8) has been reported to be released by activated peritoneal macrophages (PMs) and a variety of other cell types, and it exhibits potent chemotactic activity for polymorphonuclear cells (PMNs). We have previously shown that IL-8 is detectable in the drain dialysate of uremic patients on continuous ambulatory peritoneal dialysis (CAPD) during peritonitis. The levels of IL-8 in infected drain dialysate caused by different microorganisms were variable. In this study, we evaluated the gene expression and release of IL-8 by PMs and PMNs during peritonitis caused by Staphylococcus aureus in uremic patients on CAPD. IL-8 levels were variable in the drain dialysate at the different episodes of peritonitis, even in the same patient. The IL-8 levels were highly correlated with PMN count in drain dialysate (r=0.9919, p<0.001). PMs and PMNs obtained from drain dialysate at the onset of peritonitis increased mRNA expression for IL-8 and the amount of IL-8 mRNA from drainage cells was also highly correlated with PMN count. In contrast, cells isolated from drain dialysate without peritonitis failed to express mRNA for IL-8. These data suggest that increased expression of IL-8 may be a feature of peritonitis. The levels of IL-8 during peritonitis were not only related to the etiological microorganism but also to other unknown factor(s).
引用
收藏
页码:437 / 441
页数:5
相关论文
共 50 条
  • [31] VASOACTIVE HORMONES IN UREMIC PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    LAI, KN
    LI, PKT
    WOO, KS
    LUI, SF
    LEUNG, JCK
    LAW, E
    NICHOLLS, MG
    CLINICAL NEPHROLOGY, 1991, 35 (05) : 218 - 223
  • [32] ACINETOBACTER PERITONITIS IN PATIENTS RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    VALDEZ, JM
    ASPERILLA, MO
    SMEGO, RA
    SOUTHERN MEDICAL JOURNAL, 1991, 84 (05) : 607 - 610
  • [33] STAPH AUREUS PERITONITIS IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    KIM, D
    TAPSON, J
    WU, G
    KHANNA, R
    VAS, SI
    OREPOULOS, DG
    TRANSACTIONS AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS, 1984, 30 : 494 - 497
  • [34] CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS IMPROVES IMMUNODEFICIENCY IN UREMIC PATIENTS
    GIACCHINO, F
    QUARELLO, F
    PELLEREY, M
    PICCOLI, G
    NEPHRON, 1983, 35 (03): : 209 - 210
  • [35] OUTCOME OF POLYMICROBIAL PERITONITIS IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS PATIENTS
    KIERNAN, L
    FINKELSTEIN, FO
    KLIGER, AS
    GORBANBRENNAN, N
    JUERGENSEN, P
    MOORAKI, A
    BROWN, E
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) : 461 - 464
  • [36] FUNGAL PERITONITIS COMPLICATING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS PATIENTS
    PARK, SB
    LEE, WK
    LEE, KW
    KIM, HC
    KIM, JR
    KIDNEY INTERNATIONAL, 1991, 39 (05) : 1064 - 1064
  • [37] CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS ASSOCIATED WITH PERITONITIS IN OLDER PATIENTS
    VALENTE, J
    RAPPAPORT, W
    AMERICAN JOURNAL OF SURGERY, 1990, 159 (06): : 579 - 581
  • [38] CEFOPERAZONE IN THE TREATMENT OF PERITONITIS IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS PATIENTS
    LEEHEY, DJ
    REID, R
    CHAN, AY
    ING, TS
    ARTIFICIAL ORGANS, 1988, 12 (06) : 482 - 483
  • [39] PERITONITIS IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD)
    MAHER, TM
    ASHRAF, N
    SCHMIDT, RW
    CLINICAL RESEARCH, 1980, 28 (01): : A64 - A64
  • [40] TREATMENT OF PERITONITIS IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    HORTON, MW
    DEETER, RG
    SHERMAN, RA
    CLINICAL PHARMACY, 1990, 9 (02): : 102 - 118